MHRA opens device regulation consultation

Medical device regulation is one of those systems nobody thinks about until it slows down a product launch or blocks a hospital from buying something useful. In Great Britain, that system is still being rebuilt after Brexit. The news is that the MHRA has now put draft 2026 pre-market rules into the open and is asking industry, providers, and patients what the real-world impact will be before it finalizes them. (gov.uk) ### What actually opened this week? (gov.uk) The MHRA published draft pre-market requirements for medical devices and in vitro diagnostic devices entering the Great Britain market on the WTO notification portal on Friday, May 8, 2026, then opened a stakeholder survey on Monday, May 11. The agency is asking for comments not just from manufacturers, but also from approved bodies, healthcare providers, patients, and trade groups. (gov.uk) The deadline is 11:59 pm UK time on Friday, June 19, 2026. ### What kind of rules are these? These are the rules that matter before a device reaches the market. Basically, they decide what evidence, identifiers, classifications, and route-to-market options a manufacturer needs in order to sell in Great Britain. The MHRA says the draft sits inside the planned “Medical Devices (Amendment) Regulations 2026” and is meant to be patient-centered but also lighter-touch where possible. (gov.uk) ### What is the biggest commercial change? The headline item is a new international reliance framework. That would let some devices reach Great Britain faster if they have already been approved by regulators in Australia, Canada, or the United States. For companies, that could mean less duplicated work than a fully standalone British route. (gov.uk) But it also means manufacturers will need to understand exactly where the UK will still demand its own documentation, labeling, or post-approval controls. ### What else is in the package? There are several other changes bundled in. The draft would make unique device identifiers compulsory, require implant cards for patients who receive implantable devices, align IVD classifications with IMDRF standards, tighten technical-document retention, and add new requirements for custom-made devices. (gov.uk) The MHRA also wants manufacturers’ claims about a device to match the product’s stated intended purpose more closely. ### Why do IVD companies care so much? IVDs are tests and diagnostic systems — everything from lab analyzers to the consumables and calibration materials tied to them. Reclassification sounds abstract, but it can change what conformity assessment route a product needs and how much evidence has to sit behind it. (gov.uk) If a company sells a broad menu of assays or accessories, even a modest shift in classification or documentation rules can ripple across lots of SKUs. That is why this consultation matters beyond the biggest device makers. ### How does this fit into the wider UK rewrite? This is not a standalone surprise. The MHRA has been rolling out reform in stages. Post-market surveillance rules already came into force on June 16, 2025, and the agency has said a further statutory instrument in 2026 would handle new pre-market requirements, including international reliance. (gov.uk) Separately, Great Britain also ran a 2026 consultation on indefinitely recognizing CE-marked devices, which shows the UK is still trying to balance autonomy with not choking supply. ### So what happens next? The consultation responses feed into the impact assessment and future implementation. That means this is the stage where companies try to push for narrower definitions, longer transition periods, or cleaner alignment with global files. (gov.uk) The catch is that the broad direction now looks set — more traceability, more structured pre-market rules, and a more explicit UK position on when it will trust other regulators. ### Bottom line? This is the UK moving from reform talk to draft legal text. For medtech companies, especially diagnostics suppliers, the question is no longer whether the framework is changing. It is which products get easier access, which ones pick up new compliance work, and how fast firms need to reorganize for a more distinctly British rulebook. (gov.uk 1) (gov.uk 2)